Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Phase of Trial: Phase I/II
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Trilaciclib (Primary) ; Topotecan
- Indications Small cell lung cancer
- Focus Adverse reactions; Proof of concept
- Sponsors G1 Therapeutics
- 09 Aug 2017 According to a G1 Therapeutics media release, completion of enrollment is expected in the second quarter of 2018.
- 07 Aug 2017 Planned number of patients changed from 100 to 120.
- 07 Aug 2017 Planned End Date changed from 1 May 2018 to 1 May 2019.